Gary Clark: Unfiltered

Medical imaging innovator Nanox Imaging acquires VasoHealthcare IT to accelerate US deployment of its AI-powered diagnostics. The deal signals a shift towards integrated solutions in a rapidly evolving market.

Small-cap biotech RenovoRx presents at an investor showcase amid Phase III trial progress and growing competition in targeted cancer therapies. Is the company’s TAMP platform poised for disruption?

Facing a competitive landscape and evolving business model, Vivos Therapeutics is doubling down on direct patient access through strategic acquisitions and expanding its sleep center network. Can this strategy fuel profitability?

Hyperfine receives $3.7M from the Gates Foundation to expand access to brain imaging for infants in resource-constrained settings, leveraging AI and portable MRI technology.

NanoVibronix’s strategic shift to ENvue Medical represents a bold bet on navigation technology. The company is divesting acoustic therapies to focus on improving enteral tube placement and expanding into new applications.

NANO Nuclear Energy’s innovative pump technology is poised to unlock the potential of small modular reactors, promising durable, low-maintenance power for remote locations and beyond. But can the company scale up fast enough?

Positive Phase 3 trial data signals potential for EyePoint Pharmaceuticals’ DURAVYU to revolutionize wet AMD treatment, offering patients a less frequent alternative to monthly injections and a significant market opportunity.

Positive Phase 3 results for Agios' mitapivat in sickle cell disease are tempered by a lack of statistical significance in pain crisis reduction. Analysts weigh the implications for the rare disease drug developer.

A strategic partnership allows Scynexis to prioritize pipeline assets while GSK aims to revive a struggling antifungal, signaling a changing landscape in biotech commercialization.

Viking Therapeutics is challenging the weight loss drug landscape with VK2735, a dual GIP/GLP-1 agonist. Rapid enrollment in its Phase 3 trial signals strong demand and positions the company as a potential competitor to Wegovy and Zepbound.

Protara Therapeutics is set to release interim data on TARA-002, a novel cell therapy targeting pediatric lymphatic malformations. Experts suggest this could disrupt the rare disease treatment landscape.

The European Commission has approved Insmed’s BRINSUPRI, the first targeted therapy for non-cystic fibrosis bronchiectasis in the EU. This marks a significant step forward for the 600,000+ affected Europeans.

RespireRx Pharmaceuticals seeks a $45 million lifeline to advance neurological treatments, but a history of financial issues and delayed filings raise questions about the company's viability. A deep dive into its programs and funding strategy.

Following an SEC order revoking its stock registration, RespireRx Pharmaceuticals aims to regain compliance and advance its neurological disorder pipeline, though financial health remains a significant hurdle.

Apyx Medical Corporation secures $10 million in a public offering, bolstering its position in the expanding surgical aesthetics market and funding continued innovation in its Helium Plasma Technology platform.

Biopharmaceutical firm MediciNova appoints Dr. Christopher Breder as Clinical and Regulatory Advisor, bolstering its pipeline amidst growing competition and complexity in neurodegenerative disease treatment.

Biotech firm Invivyd secures $125 million to advance its VYD2311 antibody, targeting evolving COVID-19 variants and offering potential solutions for Long COVID. Is this funding a sign of confidence or a risky bet?

Fennec Pharmaceuticals secured $40.25 million in a public offering to advance its lead product, PEDMARK, which aims to reduce ototoxicity in cancer patients. The funding will also address debt and bolster working capital.

Apyx Medical Corporation announced a planned stock offering as it capitalizes on rising demand for minimally invasive body contouring procedures. The company’s recent financial performance and strategic expansion plans support the move.

Biopharma firm Invivyd secured $125 million in a public offering, fueling commercialization of its novel antibody, VYD2311, and expansion into RSV and measles treatments. Analysts question if the funding is enough.